BioMarin Pharmaceuticals foresees its achondroplasia drug Voxzogo (vosoritide) having a strong competitive position in the years to come given the drug’s established position and the “stickiness” of the market, meaning the tendency for patients to stick to one therapy rather than switching. Voxzogo’s solid performance contributed heavily to the firm’s fourth quarter growth.
BioMarin’s Voxzogo Expected To Benefit From ‘Sticky’ Nature Of Achondroplasia Market
Sales for the drug grew significantly, with an exec telling the fourth-quarter earnings call that patients with achondroplasia tend to stick with the drugs they are using.
More from Earnings
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
• By
Obefazimod has been heralded as a potential blockbuster for ulcerative colitis and there will be great interest in the readout of Phase III induction trials in the third quarter of this year.
More from Scrip
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.